Novo Nordisk appoints new general manager for Ireland operation

Nina Hovland heads up Irish arm of Danish firm behind weight-loss-inducing drugs Wegovy and Ozempic

Nina Hovland, new general manager for Novo Nordisk Ireland: says the firm is attempting to work to ‘prevent the onset of obesity and diabetes by driving systemic reform and addressing inherent health barriers in society’

Novo Nordisk, the Danish company behind anti-obesity drug Wegovy and Ozempic, which is used to treat diabetes, has appointed a new general manager for Ireland as it ramps up its plans to develop a production facility in Dublin.

The new general manager is Nina Hovland, a former officer with the Royal Norwegian Airforce.

Hovland has previously worked as the obesity business unit director at Novo Nordisk, and has worked in the pharmaceutical industry since 2007.